High Risk of Fractures Within 7 Years of Diagnosis in Asian Patients With Inflammatory Bowel Diseases Hyung Jin Ahn, Ye-Jee Kim, Ho-Su Lee, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Beom-Jun Kim, Sang Hyoung Park Clinical Gastroenterology and Hepatology.2022; 20(5): e1022. CrossRef
Jianpi Qingchang Bushen decoction improves inflammatory response and metabolic bone disorder in inflammatory bowel disease-induced bone loss Ya-Li Zhang, Qian Chen, Lie Zheng, Zi-Wei Zhang, Yu-Jun Chen, Yan-Cheng Dai, Zhi-Peng Tang World Journal of Gastroenterology.2022; 28(13): 1315. CrossRef
IS DAIRY FOODS RESTRICTION MANDATORY FOR INFLAMMATORY BOWEL DISEASE PATIENTS: A MULTINATIONAL CROSS-SECTIONAL STUDY Pezhman ALAVINEJAD, Morteza NAYEBI, Abazar PARSI, Farnaz FARSI, Fatemeh MAGHOOL, Zeinab ALIPOUR, Mehdi ALIMADADI, Mohammed Hussien AHMED, Bahman CHERAGHIAN, Dao Viet HANG, Shabnam SHAHROKH, Mohammad Hasan EMAMI, Seyed Jalal HASHEMI, Mohamed ALBORAIE, Damo Arquivos de Gastroenterologia.2022; 59(3): 358. CrossRef
Influence of Severe Vitamin D Deficiency on the Clinical Course of Inflammatory Bowel Disease Nam Seok Ham, Sung Wook Hwang, Eun Hye Oh, Jeongseok Kim, Ho-Su Lee, Sang Hyoung Park, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang Digestive Diseases and Sciences.2021; 66(2): 587. CrossRef
Influence of Severe Vitamin D Deficiency on the Clinical Course of Inflammatory Bowel Disease Cong Dai, Min Jiang Digestive Diseases and Sciences.2021; 66(3): 919. CrossRef
The effect of vitamin d-calcium co-supplementation on inflammatory biomarkers: A systematic review and meta-analysis of randomized controlled trials Omid Asbaghi, Mehdi Sadeghian, Hassan Mozaffari-Khosravi, Vahid Maleki, Azad Shokri, Fatemeh Hajizadeh-Sharafabad, Mohammad Alizadeh, Omid Sadeghi Cytokine.2020; 129: 155050. CrossRef
Fecal calprotectin (FC) is a highly sensitive disease activity biomarker in inflammatory bowel disease. However, there are conflicting reports on whether the diagnostic accuracy in Crohn’s disease is influenced by disease location. The aim of this study was to undertake a systematic review of the published literature. Relevant databases were searched from inception to November 8, 2016 for cohort and case control studies which had data on FC in patients with isolated small bowel (SB) and large bowel (LB) Crohn’s disease. Reference standards for disease activity were endoscopy, magnetic resonance imaging, computed tomography or a combination of these. The QUADAS-2 research tool was used to assess the risk of bias. There were 5,619 records identified at initial search. The 2,098 duplicates were removed and 3,521 records screened. Sixty-one full text articles were assessed for eligibility and 16 studies were included in the final review with sensitivities and specificities per disease location available from 8 studies. Sensitivities of FC at SB and LB locations ranged from 42.9% to 100% and 66.7% to 100% respectively while corresponding specificities were 50% to 100% and 28.6% to 100% respectively. The sensitivities and specificities of FC to accurately measure disease activity in Crohn’s disease at different disease locations are diverse and no firm conclusion can be made. Better studies need to be undertaken to categorically answer the effect of disease location on the diagnostic accuracy of FC.
Citations
Citations to this article as recorded by
Serum food specific IgG antibodies are associated with small bowel inflammation in patients with Crohn’s disease Jintong Chen, Huaning Chen, Yanni Huang, Hongchai Xie, Silin Li, Chengdang Wang European Journal of Clinical Nutrition.2024; 78(1): 48. CrossRef
Combination of leucine-rich alpha-2 glycoprotein and fecal markers detect Crohn’s disease activity confirmed by balloon-assisted enteroscopy Ami Kawamoto, Kento Takenaka, Shuji Hibiya, Yoshio Kitazume, Hiromichi Shimizu, Toshimitsu Fujii, Eiko Saito, Kazuo Ohtsuka, Ryuichi Okamoto Intestinal Research.2024; 22(1): 65. CrossRef
Which biomarkers best reflect the degree of inflammation in Crohn’s disease? Jihye Park Intestinal Research.2024; 22(1): 1. CrossRef
RNA Expression of MMP12 Is Strongly Associated with Inflammatory Bowel Disease and Is Regulated by Metabolic Pathways in RAW 264.7 Macrophages Laura Arosa, Miguel Camba-Gómez, Luis Francisco Lorenzo-Martín, Laura Clavaín, Miguel López, Javier Conde-Aranda International Journal of Molecular Sciences.2024; 25(6): 3167. CrossRef
Circulatory resistin levels in inflammatory bowel disease: a systematic review and meta-analysis Amir Hossein Behnoush, Seyede Parmis Maroufi, Tara Reshadmanesh, Yasmin Mohtasham Kia, Mitra Norouzi, Seyedeh Mina Mohammadi, Aleksandra Klisic, Amirmohammad Khalaji BMC Gastroenterology.2024;[Epub] CrossRef
Application of clinical decision support tools for predicting outcomes with vedolizumab therapy in patients with inflammatory bowel disease: A KASID multicentre study Kyuwon Kim, Jae Jun Park, Hyuk Yoon, Jun Lee, Kyeong Ok Kim, Eun Sun Kim, Su Young Kim, Sun‐Jin Boo, Yunho Jung, Jun Hwan Yoo, Sung Wook Hwang, Sang Hyoung Park, Suk‐Kyun Yang, Byong Duk Ye Alimentary Pharmacology & Therapeutics.2024; 59(12): 1539. CrossRef
Fecal Calprotectin in Patients with Crohn’s Disease: A Study Based on the History of Bowel Resection and Location of Disease Jeongkuk Seo, Subin Song, Seung Hwan Shin, Suhyun Park, Seung Wook Hong, Sang Hyoung Park, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Sung Wook Hwang Diagnostics.2024; 14(8): 854. CrossRef
Utility of the Endoscopic Healing Index in Identifying Active Inflammation in Patients with Crohn’s Disease: Real World Data from a Tertiary Center Nathaniel A. Cohen, Tenzin Choden, Emma C. Dyer, Nicole M. Garcia, Natalie K. Choi, David T. Rubin Digestive Diseases and Sciences.2024; 69(8): 2955. CrossRef
Diagnostic Value of Quantitative Contrast‐Enhanced Ultrasound in Comparison to Endoscopy in Children With Crohn's Disease Slavojka Ponorac, Raja Dahmane Gošnak, Darja Urlep, Damjana Ključevšek Journal of Ultrasound in Medicine.2023; 42(1): 193. CrossRef
Resistin, Elastase, and Lactoferrin as Potential Plasma Biomarkers of Pediatric Inflammatory Bowel Disease Based on Comprehensive Proteomic Screens Anto Sam Crosslee Louis Sam Titus, Kamala Vanarsa, Sanam Soomro, Anjali Patel, Jarod Prince, Subra Kugathasan, Chandra Mohan Molecular & Cellular Proteomics.2023; 22(2): 100487. CrossRef
Fecal immunochemical test for haemoglobin versus fecal calprotectin to monitoring endoscopic activity in inflammatory bowel disease Patricia Latorre Añó, Jorge Torrente Sánchez, Amparo Almudena Pérez Ibañez, Jose María Tenias Burillo, Nadia Paloma Moreno Sánchez, Antonio López-Serrano, Eduardo Moreno Osset, Julián Murado Pardo, José María Paredes Revista Española de Enfermedades Digestivas.2023;[Epub] CrossRef
Clinical Value of Detecting Fecal Calprotectin by Using Colloidal Gold Assay in Screening or Diagnosing Crohn’s Disease Wangdong Zhang, Yanyun Fan, Meijun Chen, Tatsuya Toyokawa Gastroenterology Research and Practice.2023; 2023: 1. CrossRef
AGA Clinical Practice Guideline on the Role of Biomarkers for the Management of Crohn’s Disease Ashwin N. Ananthakrishnan, Jeremy Adler, Karen A. Chachu, Nghia H. Nguyen, Shazia M. Siddique, Jennifer M. Weiss, Shahnaz Sultan, Fernando S. Velayos, Benjamin L. Cohen, Siddharth Singh Gastroenterology.2023; 165(6): 1367. CrossRef
Amplification of an Electrochemiluminescence-Emissive Aptamer into DNA Nanotags for Sensitive Fecal Calprotectin Determination Fujin Lv, Jialiang Chen, Ying Wan, Jingyi Si, Meiyan Song, Fulin Zhu, Songyuan Du, Yuzhe Shang, Tiantian Man, Longyi Zhu, Kewei Ren, Yuhao Piao, Changfeng Zhu, Sheng-Yuan Deng Analytical Chemistry.2023; 95(50): 18564. CrossRef
Association between Fecal Calprotectin and Mucosal Healing in Pediatric Patients with Crohn’s Disease Who Have Achieved Sustained Clinical Remission with Anti-Tumor Necrosis Factor Agents Yoo Min Lee, Sujin Choi, Byung-Ho Choe, Hyo-Jeong Jang, Seung Kim, Hong Koh, Eun Sil Kim, Mi Jin Kim, Yon Ho Choe, Ben Kang Gut and Liver.2022; 16(1): 62. CrossRef
Efficacy of sigmoidoscopy for evaluating disease activity in patients with ulcerative colitis Su Bum Park, Seong-Jung Kim, Jun Lee, Yoo Jin Lee, Dong Hoon Baek, Geom Seog Seo, Eun Soo Kim, Sang-Wook Kim, So Yeong Kim BMC Gastroenterology.2022;[Epub] CrossRef
Fungi Jane Alookaran, Yuying Liu, Thomas A. Auchtung, Amirali Tahanan, Manouchehr Hessabi, Parisa Asgarisabet, Mohammad H. Rahbar, Nicole Y. Fatheree, Deborah A. Pearson, Rosleen Mansour, Melissa R. Van Arsdall, Fernando Navarro, J. Marc Rhoads Journal of Pediatric Gastroenterology and Nutrition.2022; 74(3): 377. CrossRef
Fecal S100A12 is associated with future hospitalization and step-up of medical treatment in patients with Crohn’s disease in clinical remission: a pilot study Sun-Ho Lee, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Byong Duk Ye Intestinal Research.2022; 20(2): 203. CrossRef
Ultrasonographic scores for ileal Crohn’s disease assessment: Better, worse or the same as contrast-enhanced ultrasound? M. Freitas, F. Dias de Castro, V. Macedo Silva, C. Arieira, T. Cúrdia Gonçalves, S. Leite, M. J. Moreira, J. Cotter BMC Gastroenterology.2022;[Epub] CrossRef
Intestinal fatty acid binding protein is a disease biomarker in paediatric coeliac disease and Crohn’s disease Michael Logan, Mary MacKinder, Clare Martha Clark, Aikaterini Kountouri, Mwansa Jere, Umer Zeeshan Ijaz, Richard Hansen, Paraic McGrogan, Richard K. Russell, Konstantinos Gerasimidis BMC Gastroenterology.2022;[Epub] CrossRef
Usefulness of ultrasonography for small intestinal evaluations in pediatric Crohn's disease Takeru Okuhira, Atsushi Yoden, Emiri Kaji, Masano Otani‐Akamatsu, Keisuke Inoue, Tomoki Aomatsu, Kimitaka Takitani, Akira Ashida Pediatrics International.2022;[Epub] CrossRef
Intestinal ultrasonography and fecal calprotectin for monitoring inflammation of ileal Crohn’s disease: two complementary tests José María Paredes, Tomás Ripollés, Ángela Algarra, Rafael Diaz, Nadia Moreno, Patricia Latorre, María Jesús Martínez, Pilar Llopis, Antonio López, Eduardo Moreno-Osset Intestinal Research.2022; 20(3): 361. CrossRef
Fecal calprotectin predicts endoscopic activity and mucosal healing of small bowel Crohn’s disease evaluated by double-balloon endoscopy Wei Han, Juan Wu, Peipei Zhang, Naizhong Hu, Qiao Mei, Jing Hu International Journal of Colorectal Disease.2022; 37(9): 1953. CrossRef
Fecal Calprotectin for Small Bowel Crohn’s Disease: Is It a Cutoff Issue? Cristina Romero-Mascarell, Gloria Fernández-Esparrach, Cristina Rodríguez-De Miguel, Maria Carme Masamunt, Sonia Rodríguez, Jordi Rimola, Miguel Urpí, Gherzon Simon Casanova, Ingrid Ordás, Elena Ricart, Berta Caballol, Agnès Fernández-Clotet, Julià Panés, Diagnostics.2022; 12(9): 2226. CrossRef
A Practical Guide for Faecal Calprotectin Measurement: Myths and Realities Ferdinando D’Amico, Stéphane Nancey, Silvio Danese, Laurent Peyrin-Biroulet Journal of Crohn's and Colitis.2021; 15(1): 152. CrossRef
The utility of faecal and urine biomarkers for small bowel diseases M.S. Ismail, Serhiy Semenov, Deirdre McNamara Current Opinion in Gastroenterology.2021; 37(3): 284. CrossRef
Predicting disease course in ulcerative colitis using stool proteins identified through an aptamer-based screen Sanam Soomro, Suresh Venkateswaran, Kamala Vanarsa, Marwa Kharboutli, Malavika Nidhi, Ramya Susarla, Ting Zhang, Prashanth Sasidharan, Kyung Hyun Lee, Joel Rosh, James Markowitz, Claudia Pedroza, Lee A. Denson, Jeffrey Hyams, Subra Kugathasan, Chandra Moh Nature Communications.2021;[Epub] CrossRef
Anti-Microbial Antibody Response is Associated With Future Onset of Crohn’s Disease Independent of Biomarkers of Altered Gut Barrier Function, Subclinical Inflammation, and Genetic Risk Sun-Ho Lee, Williams Turpin, Osvaldo Espin-Garcia, Juan Antonio Raygoza Garay, Michelle I. Smith, Haim Leibovitzh, Ashleigh Goethel, Dan Turner, David Mack, Colette Deslandres, Maria Cino, Guy Aumais, Remo Panaccione, Kevan Jacobson, Alain Bitton, A. Hill Gastroenterology.2021; 161(5): 1540. CrossRef
Diagnostic Accuracy of Fecal Calprotectin for the Detection of Small Bowel Crohn's Disease through Capsule Endoscopy: An Updated Meta-Analysis and Systematic Review Eun Suk Jung, Sang Pyo Lee, Sea Hyub Kae, Jung Han Kim, Hyeong Su Kim, Hyun Joo Jang Gut and Liver.2021; 15(5): 732. CrossRef
Optimal Cutoff Level of Fecal Calprotectin for Detecting Small Bowel Inflammation in Crohn's Disease Eun Soo Kim Gut and Liver.2021; 15(5): 637. CrossRef
Diagnostic Accuracy of Non-Invasive Imaging for Detection of Colonic Inflammation in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis Meshari T. Alshammari, Rebecca Stevenson, Buraq Abdul-Aema, Guangyong Zou, Vipul Jairath, Shellie Radford, Luca Marciani, Gordon W. Moran Diagnostics.2021; 11(10): 1926. CrossRef
Közös felelősség a gyulladásos bélbetegség diagnosztikájában és kezelésében. Dóra Dohos, Adrienn Erős, Kata Szemes, Patrícia Sarlós Orvosi Hetilap.2021; 162(33): 1311. CrossRef
Crohn's Disease Activity Quantified by Iodine Density Obtained From Dual-Energy Computed Tomography Enterography Bari Dane, Sean Duenas, Joseph Han, Thomas O'Donnell, Justin Ream, Shannon Chang, Alec Megibow Journal of Computer Assisted Tomography.2020; 44(2): 242. CrossRef
Defining the Path Forward for Biomarkers to Address Unmet Needs in Inflammatory Bowel Diseases Gerard Honig, Caren Heller, Andrés Hurtado-Lorenzo Inflammatory Bowel Diseases.2020; 26(10): 1451. CrossRef
Multiomic features associated with mucosal healing and inflammation in paediatric Crohn’s disease Henry Taylor, Jose Ivan Serrano‐Contreras, Julie A. K. McDonald, Jenny Epstein, JM Fell, Rocio C. Seoane, Jia V. Li, Julian R. Marchesi, Ailsa L. Hart Alimentary Pharmacology & Therapeutics.2020; 52(9): 1491. CrossRef
Nested case-control study on risk factors for opportunistic infections in patients with inflammatory bowel disease Shan-Shan Gong, Yi-Hong Fan, Qing-Qing Han, Bin Lv, Yi Xu World Journal of Gastroenterology.2019; 25(18): 2240. CrossRef
Clinical value of fecal calprotectin Amanda Ricciuto, Anne M. Griffiths Critical Reviews in Clinical Laboratory Sciences.2019; 56(5): 307. CrossRef
The role and efficacy of exclusive enteral nutrition (EEN) in the treatment of luminal Crohn’s disease (CD) has been well established over the last 2 decades. Consequently, in many centers nutritional therapy is now considered first line therapy in the induction of remission of active CD. However, the use of nutritional therapy in complicated CD has yet to be fully determined. This article aimed to review case reports and clinical trials published in the last decade that have considered and evaluated nutritional therapy in the setting of complicated CD in children and adults. Published literature focusing upon the use of nutritional therapy as part of medical therapy in the management of complicated CD were identified and reviewed. Although there continue to be various interventions utilized for complicated CD, the currently available literature demonstrates that nutritional therapies, especially EEN, have important roles in the management of these complex scenarios. Further assessments, involving large numbers of patients managed with consistent approaches, are required to further substantiate these roles.
Citations
Citations to this article as recorded by
Mycobacterium avium ssp. paratuberculosis and Crohn’s Disease—Diagnostic Microbiological Investigations Can Inform New Therapeutic Approaches John M. Aitken, Jack E. Aitken, Gaurav Agrawal Antibiotics.2024; 13(2): 158. CrossRef
Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) (Version 4.1) – living guideline Andreas Sturm, Raja Atreya, Dominik Bettenworth, Bernd Bokemeyer, Axel Dignass, Robert Ehehalt, Christoph-Thomas Germer, P. C. Grunert, Ulf Helwig, Karoline Horisberger, Klaus Herrlinger, Peter Kienle, Torsten Kucharzik, Jost Langhorst, Christian Maaser, Zeitschrift für Gastroenterologie.2024; 62(08): 1229. CrossRef
Mechanisms of Action of Exclusive Enteral Nutrition and Other Nutritional Therapies in Crohn’s Disease Ramasatyaveni Geesala, Pratik Gongloor, Neeraja Recharla, Xuan-Zheng Shi Nutrients.2024; 16(21): 3581. CrossRef
Adjunct polymeric exclusive enteral nutrition helps achieve biochemical remission in active Crohn’s disease in adults irrespective of disease location and concomitant corticosteroid use Hellen Kuo, Katrina Tognolini, Rumbidzai Mutsekwa, Dheeraj Shukla, Laura Willmann, Hadi Moattar, Alexander Dorrington, Naveed Ishaq, Maneesha Bhullar, John Edwards, Waled Mohsen, Pradeep Kakkadasam Ramaswamy Frontline Gastroenterology.2024; : flgastro-2024-102749. CrossRef
Is Salt at Fault? Dietary Salt Consumption and Inflammatory Bowel Disease Rebecca Kuang, Stephen J D O’Keefe, Claudia Ramos del Aguila de Rivers, Filippos Koutroumpakis, David G Binion Inflammatory Bowel Diseases.2023; 29(1): 140. CrossRef
The Role of the Gut Microbiota in the Relationship Between Diet and Human Health Bryce K. Perler, Elliot S. Friedman, Gary D. Wu Annual Review of Physiology.2023; 85(1): 449. CrossRef
Global research trends on diet and nutrition in Crohn’s disease Muna Shakhshir, Sa'ed H Zyoud World Journal of Gastroenterology.2023; 29(20): 3203. CrossRef
Enterale Ernährungstherapien beim pädiatrischen M.
Crohn Anwendungen und Wirkweise André Hörning, Anjona Schmidt-Choudhury Aktuelle Ernährungsmedizin.2023; 48(03): 183. CrossRef
Identifying Microbiome Dynamics in Pediatric IBD: More than a Family Matter Nikolas Dovrolis, Anastasia Moschoviti, Smaragdi Fessatou, George Karamanolis, George Kolios, Maria Gazouli Biomedicines.2023; 11(7): 1979. CrossRef
Unraveling the Impact of Gut and Oral Microbiome on Gut Health in Inflammatory Bowel Diseases Hala Elzayat, Ghaidaa Mesto, Farah Al-Marzooq Nutrients.2023; 15(15): 3377. CrossRef
Interplay between inflammatory bowel disease therapeutics and the gut microbiome reveals opportunities for novel treatment approaches Catherine O’Reilly, Susan Mills, Mary C. Rea, Aonghus Lavelle, Subrata Ghosh, Colin Hill, R. Paul Ross Microbiome Research Reports.2023;[Epub] CrossRef
Current understanding of the aetiology and pathogenesis of inflammatory bowel diseases (Part 2): the role of the microbiome and nutritional factors A. I. Khavkin, K. M. Nikolaychuk, E. V. Shrayner, D. R. Shaimardanova, A. S. Veremenko, I. D. Levchenko, P. Ya. Platonova, M. F. Novikova, V. V. Dudurich Experimental and Clinical Gastroenterology.2023; (12): 164. CrossRef
FODMAPs, inflammatory bowel disease and gut microbiota: updated overview on the current evidence Catarina D. Simões, Marta Maganinho, Ana S. Sousa European Journal of Nutrition.2022; 61(3): 1187. CrossRef
Effects of Olive Oil and Its Components on Intestinal Inflammation and Inflammatory Bowel Disease Josip Vrdoljak, Marko Kumric, Marino Vilovic, Dinko Martinovic, Iris Jeroncic Tomic, Mladen Krnic, Tina Ticinovic Kurir, Josko Bozic Nutrients.2022; 14(4): 757. CrossRef
Exclusive enteral nutrition: An optimal care pathway for use in children with active luminal Crohn's disease Deirdre Burgess, Kathleen H McGrath, Caitlin Watson, Tanya Collins, Stephanie Brown, Katie Marks, Kate Dehlsen, Kim Herbison, Emma Landorf, Laura Benn, Julia Fox, Ming Liew Journal of Paediatrics and Child Health.2022; 58(4): 572. CrossRef
Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – August 2021 – AWMF-Registernummer: 021-004 Andreas Sturm, Raja Atreya, Dominik Bettenworth, Bernd Bokemeyer, Axel Dignaß, Robert Ehehalt, Christoph Germer, Philip C. Grunert, Ulf Helwig, Klaus Herrlinger, Peter Kienle, Martin E. Kreis, Torsten Kucharzik, Jost Langhorst, Christian Maaser, Johann Oc Zeitschrift für Gastroenterologie.2022; 60(03): 332. CrossRef
The Optimal Management of Fistulizing Crohn’s Disease: Evidence beyond Randomized Clinical Trials Panu Wetwittayakhlang, Alex Al Khoury, Gustavo Drügg Hahn, Peter Laszlo Lakatos Journal of Clinical Medicine.2022; 11(11): 3045. CrossRef
Laser Therapy in Perianal Fistulas Mircea Sandor, Maur Sebastian Horgos, Ioan Lucian Borza, Rodica Negrean, Mihai Botea, Szuhai Erika Bimbo, Anca Huniadi, Liliana Sachelarie, Loredana Liliana Hurjui, Irina Mihaela Jemnoschi Hreniuc Applied Sciences.2022; 12(23): 12433. CrossRef
Enterale Ernährungstherapien beim pädiatrischen M. Crohn André Hörning, Anjona Schmidt-Choudhury Kinder- und Jugendmedizin.2022; 22(06): 439. CrossRef
Dietary patterns, beliefs and behaviours among individuals with inflammatory bowel disease: a cross‐sectional study K. J. Kamp, B. Pennings, D. Javelli, G. Wyatt, B. Given Journal of Human Nutrition and Dietetics.2021; 34(2): 257. CrossRef
Alterations in drug disposition in older adults: a focus on geriatric syndromes Dorsa Maher, Nagham Ailabouni, Arduino A. Mangoni, Michael D. Wiese, Emily Reeve Expert Opinion on Drug Metabolism & Toxicology.2021; 17(1): 41. CrossRef
Nutritional Therapy Strategies in Pediatric Crohn’s Disease Charlotte M. Verburgt, Mohammed Ghiboub, Marc A. Benninga, Wouter J. de Jonge, Johan E. Van Limbergen Nutrients.2021; 13(1): 212. CrossRef
Enteral nutrition modulation with n-3 PUFAs directs microbiome and lipid metabolism in mice Fuzheng Tao, Xi Xing, Jiannong Wu, Ronglin Jiang, Tamil Selvan Anthonymuthu PLOS ONE.2021; 16(3): e0248482. CrossRef
Fish Sidestream-Derived Protein Hydrolysates Suppress DSS-Induced Colitis by Modulating Intestinal Inflammation in Mice Maria G. Daskalaki, Konstantinos Axarlis, Tone Aspevik, Michail Orfanakis, Ourania Kolliniati, Ioanna Lapi, Maria Tzardi, Eirini Dermitzaki, Maria Venihaki, Katerina Kousoulaki, Christos Tsatsanis Marine Drugs.2021; 19(6): 312. CrossRef
Risk Factors for Disease Behavior Evolution and Efficacy of Biologics in Reducing Progression in Pediatric Patients with Nonstricturing, Nonpenetrating Crohn's Disease at Diagnosis: A Single-Center Experience in Korea Hyun Jin Kim, Seak Hee Oh, Sung Hee Lee, Yu-Bin Kim, Dae Yeon Kim, Sang Hyoung Park, Byong Duk Ye, Suk-Kyun Yang, Kyung Mo Kim Gut and Liver.2021; 15(6): 851. CrossRef
The Effect of Formula-based Nutritional Treatment on Colitis in a Murine Model Sooyoung Jang, Younjuong Kim, Changjun Lee, Bomi Kwon, Jihye Noh, Jai J. Jee, Sang Sun Yoon, Hong Koh, Sowon Park Journal of Korean Medical Science.2021;[Epub] CrossRef
Inflammatory bowel diseases (IBD) are chronic conditions of the gastrointestinal tract-the main site of host-microbial interaction in the body. Development of IBD is not due to a single event but rather is a multifactorial process where a patient’s genetic background, behavioral habits, and environmental exposures contribute to disease pathogenesis. IBD patients exhibit alterations to gut bacterial populations “dysbiosis” due to the inflammatory microenvironment, however whether this alteration of the gut microbiota precedes inflammation has not been confirmed. Emerging evidence has highlighted the important role of gut microbes in developing measured immune responses and modulating other host responses such as metabolism. Much of the work on the gut microbiota has been correlative and there is an increasing need to understand the intimate relationship between host and microbe. In this review, we highlight how commensal and pathogenic bacteria interact with host intestinal epithelial cells and explore how altered microenvironments impact these connections.
Citations
Citations to this article as recorded by
Space Radiation-induced Impacts on Gut Flora, Metabolites and Multisystem Diseases Zhujun WU, Xin ZHANG, Yudi PANG, Yulin DENG, Zhimin WANG Chinese Journal of Space Science.2024; 44(5): 873. CrossRef
Host–pathobiont interactions in Crohn’s disease Roberta Caruso, Bernard C. Lo, Grace Y. Chen, Gabriel Núñez Nature Reviews Gastroenterology & Hepatology.2024;[Epub] CrossRef
Assembling symbiotic bacterial species into live therapeutic consortia that reconstitute microbiome functions Rita A. Oliveira, Eric G. Pamer Cell Host & Microbe.2023; 31(4): 472. CrossRef
Direct and Indirect Evidence of Effects of Bacteroides spp. on Obesity and Inflammation Liangliang Wu, Seo-Hyun Park, Hojun Kim International Journal of Molecular Sciences.2023; 25(1): 438. CrossRef
Inflammatory bowel disease: The role of commensal microbiome in immune regulation Martín Ivan Wah-Suárez, Manuel Alejandro Martínez Vázquez, Francisco Javier Bosques-Padilla Gastroenterología y Hepatología.2022; 45(8): 626. CrossRef
Novel Potassium-Competitive Acid Blocker, Tegoprazan, Protects Against Colitis by Improving Gut Barrier Function Mijeong Son, I Seul Park, Soochan Kim, Hyun Woo Ma, Ji Hyung Kim, Tae Il Kim, Won Ho Kim, Jaeyong Han, Seung Won Kim, Jae Hee Cheon Frontiers in Immunology.2022;[Epub] CrossRef
Inflammatory bowel disease in Korea: epidemiology and pathophysiology Jung Won Lee, Chang Soo Eun The Korean Journal of Internal Medicine.2022; 37(5): 885. CrossRef
Inflammatory bowel disease: The role of commensal microbiome in immune regulation Martín Ivan Wah-Suárez, Manuel Alejandro Martínez Vázquez, Francisco Javier Bosques-Padilla Gastroenterología y Hepatología (English Edition).2022; 45(8): 626. CrossRef
Effects of hypoxia stress on the intestinal microflora of juvenile of cobia (Rachycentron canadum) Wei-zheng Wang, Jian-sheng Huang, Jian-dong Zhang, Zhong-liang Wang, Hong-juan Li, Eric Amenyogbe, Gang Chen Aquaculture.2021; 536: 736419. CrossRef
Intestinal microbiota and inflammatory bowel diseases Chang Soo Eun Journal of the Korean Medical Association.2021; 64(9): 588. CrossRef
Glutathione S‐transferase theta 1 protects against colitis through goblet cell differentiation via interleukin‐22 Jae Hyeon Kim, Jae Bum Ahn, Da Hye Kim, Soochan Kim, Hyun Woo Ma, Xiumei Che, Dong Hyuk Seo, Tae Il Kim, Won Ho Kim, Jae Hee Cheon, Seung Won Kim The FASEB Journal.2020; 34(2): 3289. CrossRef
Pathogenesis and clinical perspectives of extraintestinal manifestations in inflammatory bowel diseases Jung Min Kim, Jae Hee Cheon Intestinal Research.2020; 18(3): 249. CrossRef
The impact of maternal and early life malnutrition on health: a diet-microbe perspective Andrew J. Forgie, Kelsea M. Drall, Stephane L. Bourque, Catherine J. Field, Anita L. Kozyrskyj, Benjamin P. Willing BMC Medicine.2020;[Epub] CrossRef
Melatonin in the colon modulates intestinal microbiota in response to stress and sleep deprivation Young Sook Park, Soo Hyung Kim, Jong Won Park, Younglim Kho, Pu Rum Seok, Jae-Ho Shin, Yoon Ji Choi, Jin-Hyun Jun, Hee Chan Jung, Eun Kyung Kim Intestinal Research.2020; 18(3): 325. CrossRef
Role of the microbiota in ileitis of a mouse model of inflammatory bowel disease—Glutathione peroxide isoenzymes 1 and 2‐double knockout mice on a C57BL background Fong‐Fong Chu, R. Steven Esworthy, Binghui Shen, James H. Doroshow MicrobiologyOpen.2020;[Epub] CrossRef
Patients with Inflammatory Bowel Disease Are at an Increased Risk of Parkinson’s Disease: A South Korean Nationwide Population-Based Study Seona Park, Jihye Kim, Jaeyoung Chun, Kyungdo Han, Hosim Soh, Eun Ae Kang, Hyun Jung Lee, Jong Pil Im, Joo Sung Kim Journal of Clinical Medicine.2019; 8(8): 1191. CrossRef
Background/Aims Cronobacter sakazakii, an emergent pathogen is considered as a major concern to infants and neonates fed on reconstituted powdered infant milk formula. In conjunction with many other factors, biofilm forming capacity adds to its pathogenic potential. In view of the facts that infants are at highest risk to C. sakazakii infections, and emerging antibiotic resistance among pathogens, it is imperative to evaluate probiotic cultures for their efficacy against C. sakazakii. Therefore, pure probiotic strains were isolated from commercial probiotic products and tested for their antimicrobial and anti-biofilm activities against C. sakazakii.
Methods A total of 6 probiotic strains were tested for their antibiotic susceptibility followed by antimicrobial activity using cell-free supernatant (CFS) against C. sakazakii. The inhibitory activity of CFS against biofilm formation by C. sakazakii was determined using standard crystal violet assay and microscopic observations.
Results All the probiotic strains were sensitive to ampicillin, tetracycline, vancomycin and carbenicillin whereas most of the strains were resistant to erythromycin and novobiocin. Four of the 6 probiotic derived CFS possessed antimicrobial activity against C. sakazakii at a level of 40 μL. A higher biofilm inhibitory activity (>80%) was observed at initial stages of biofilm formation with weaker activity during longer incubation upto 48 hours (50%–60%).
Conclusions The study indicated the efficacy of isolated commercial probiotics strains as potential inhibitor of biofilm formation by C. sakazakii and could be further explored for novel bioactive molecules to limit the emerging infections of C. sakazakii.
Citations
Citations to this article as recorded by
Investigating the effect of Lactiplantibacillus plantarum TW57-4 in preventing biofilm formation and expression of virulence genes in Listeria monocytogenes ATCC 19115 Arezou Rouhi, Fereshteh Falah, Marjan Azghandi, Behrooz Alizadeh Behbahani, Seyed Ali Mortazavi, Farideh Tabatabaei-Yazdi, Alireza Vasiee LWT.2024; 191: 115669. CrossRef
Exploring Technological, Safety and Probiotic Properties of Enterococcus Strains: Impact on Rheological Parameters in Fermented Milk Souraya Sakoui, Reda Derdak, Oana Lelia Pop, Dan Cristian Vodnar, Fatimazahra Jouga, Bernadette-Emőke Teleky, Boutaina Addoum, Elemér Simon, Ramona Suharoschi, Abdelaziz Soukri, Bouchra El Khalfi Foods.2024; 13(4): 586. CrossRef
Determination of Antioxidant and Antimicrobial Activities of Cell-Free Supernatant (CFSKC27L) and Exopolysaccharide (EPSKC27L) obtained from Ligilactobacillus salivarius KC27L Kübra Çelik, Zehranur Yuksekdag, Berat Çınar Acar, Filiz Kara Tekirdağ Ziraat Fakültesi Dergisi.2024; 21(4): 928. CrossRef
Limosilactobacillus fermentum
MYSY8, a Potential Probiotic Isolate from Fermented Rice Beverage for the Control of
Microsporum canis
Padur Ramachandra Vanitha, Divyashree Shivakumar, Shruthi Basavaraj, Adithi Gunduraj, Dhanuja Janardanachar, Deepthi BV, Marikunte Yanjarappa Sreenivasa Food Biotechnology.2024; 38(3): 314. CrossRef
Multivariate analysis of structural and functional properties of fibres from apple pomace using different extraction methods Rusli Fidriyanto, Brij Pal Singh, K. M. Manju, Yantyati Widyastuti, Gunjan Goel Food Production, Processing and Nutrition.2023;[Epub] CrossRef
Antifungal activity of probiotic strain Lactiplantibacillus plantarum MYSN7 against Trichophyton tonsurans P. R. Vanitha, Rakesh Somashekaraiah, S. Divyashree, Indranil Pan, M. Y. Sreenivasa Frontiers in Microbiology.2023;[Epub] CrossRef
Synergistic combination of malic acid with sodium hypochlorite impairs biofilm of Cronobacter sakazakii Rajni Chauhan, Savita Kumari, Gunjan Goel, Wamik Azmi LWT.2022; 155: 112902. CrossRef
Antibacterial and Antibiofilm Effect of Cell-Free Supernatant of Lactobacillus brevis KCCM 202399 Isolated from Korean Fermented Food against Streptococcus mutans KCTC 5458 Jong Ha Kim, Hye Ji Jang, Na-Kyoung Lee, Hyun-Dong Paik Journal of Microbiology and Biotechnology.2022; 32(1): 56. CrossRef
Selection of a Potential Synbiotic against Cronobacter sakazakii
ALFRED KE, VALERIA R. PARREIRA, JEFFREY M. FARBER, LAWRENCE GOODRIDGE Journal of Food Protection.2022; 85(9): 1240. CrossRef
Black cherry fruit as a source of probiotic candidates with antimicrobial and antibiofilm activities against Salmonella S. Divyashree, P.G Anjali, B.V. Deepthi, Rakesh Somashekaraiah, Walid Mottawea, Riadh Hammami, M.Y. Sreenivasa South African Journal of Botany.2022; 150: 861. CrossRef
Anti-biofilm effect of the cell-free supernatant of probiotic Saccharomyces cerevisiae against Listeria monocytogenes Yeon Jin Kim, Hwan Hee Yu, Ye Ji Song, Yeong Jin Park, Na-Kyoung Lee, Hyun-Dong Paik Food Control.2021; 121: 107667. CrossRef
Probiotic properties of Lactobacillus casei – MYSRD 108 and Lactobacillus plantarum-MYSRD 71 with potential antimicrobial activity against Salmonella paratyphi S. Divyashree, P.G. Anjali, Rakesh Somashekaraiah, M.Y. Sreenivasa Biotechnology Reports.2021; 32: e00672. CrossRef
Intestinal microbiota and inflammatory bowel diseases Chang Soo Eun Journal of the Korean Medical Association.2021; 64(9): 588. CrossRef
Current and Future Perspectives on the Role of Probiotics, Prebiotics, and Synbiotics in Controlling Pathogenic Cronobacter Spp. in Infants Alfred Ke, Valeria R. Parreira, Lawrence Goodridge, Jeffrey M. Farber Frontiers in Microbiology.2021;[Epub] CrossRef
Impairment of Cronobacter sakazakii and Listeria monocytogenes biofilms by cell-free preparations of lactobacilli of goat milk origin Niharika Singh, Ravinder Kaur, Brij Pal Singh, Namita Rokana, Gunjan Goel, Anil Kumar Puniya, Harsh Panwar Folia Microbiologica.2020; 65(1): 185. CrossRef
The Battle of Probiotics and Their Derivatives Against Biofilms
Abolfazl Barzegari, Keyvan Kheyrolahzadeh, Seyed Mahdi Hosseiniyan Khatibi, Simin Sharifi, Mohammad Yousef Memar, Sepideh Zununi Vahed Infection and Drug Resistance.2020; Volume 13: 659. CrossRef
Postbiotics against Pathogens Commonly Involved in Pediatric Infectious Diseases Anastasia Mantziari, Seppo Salminen, Hania Szajewska, Jeadran Nevardo Malagón-Rojas Microorganisms.2020; 8(10): 1510. CrossRef
Background/Aims Fecal calprotectin (Fcal) as well as the fecal immunochemical test (FIT) are useful biomarkers for detecting activity and mucosal healing in inflammatory bowel diseases. Here, we report the performance of simultaneous measurements of Fcal and FIT for ulcerative colitis (UC) patients using the newly-developed latex agglutination turbidimetric immunoassay (LATIA) system.
Methods Fcal and hemoglobin were measured by the LATIA system in 152 UC patients who underwent colonoscopy. Fcal was also quantified with a conventional enzyme-linked immunosorbent assay (ELISA). Fecal markers were evaluated in conjunction with the mucosal status of UC, which was assessed via the Mayo endoscopic subscore (MES) classification.
Results The LATIA system could quantify calprotectin and hemoglobin simultaneously with the same fecal samples within 10 minutes. The values of the Fcal-LATIA closely correlated with those of the Fcal-ELISA (Spearman rank correlation coefficient, r=0.84; P<0.0001). The values of Fcal for each assay and the FIT all significantly correlated with the MESs (Spearman rank correlation coefficient, Fcal-LATIA: r=0.58, Fcal-ELISA: r=0.55, and FIT: r=0.72). The mucosal healing predictability (determined by an MES of 0 alone) of the Fcal-LATIA, Fcal-ELISA, and FIT-LATIA with the cutoffs determined by receiver operating characteristic curve analysis was 0.79, 0.78, and 0.92 for sensitivity, respectively, and 0.78, 0.69, and 0.73 for specificity, respectively.
Conclusions The performance of the novel Fcal-LATIA was equivalent to that of the conventional Fcal assay. Simultaneous measurements with FITs would promote the clinical relevance of fecal biomarkers in UC.
Citations
Citations to this article as recorded by
Systematic scoping review: Use of the faecal immunochemical test residual buffer to enhance colorectal cancer screening Timothy McAuliffe, Joseph C. Anderson, Robin J. Larson, Douglas J. Robertson Alimentary Pharmacology & Therapeutics.2024; 59(9): 1033. CrossRef
Evaluation of a faecal calprotectin method using the OC-SENSOR PLEDIA Shane O’Driscoll, Carolyn Piggott, Sally C. Benton Clinical Chemistry and Laboratory Medicine (CCLM).2022; 60(6): 901. CrossRef
International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases Ferdinando D'Amico, David T. Rubin, Paulo Gustavo Kotze, Fernando Magro, Britta Siegmund, Taku Kobayashi, Pablo A. Olivera, Peter Bossuyt, Lieven Pouillon, Edouard Louis, Eugeni Domènech, Subrata Ghosh, Silvio Danese, Laurent Peyrin‐Biroulet United European Gastroenterology Journal.2021; 9(4): 451. CrossRef
Faecal Calprotectin in Assessment of Mucosal Healing in Adults with Inflammatory Bowel Disease: A Meta-Analysis Mariusz A. Bromke, Katarzyna Neubauer, Radosław Kempiński, Małgorzata Krzystek-Korpacka Journal of Clinical Medicine.2021; 10(10): 2203. CrossRef
Leucine-rich alpha-2 glycoprotein as a marker of mucosal healing in inflammatory bowel disease Eriko Yasutomi, Toshihiro Inokuchi, Sakiko Hiraoka, Kensuke Takei, Shoko Igawa, Shumpei Yamamoto, Masayasu Ohmori, Shohei Oka, Yasushi Yamasaki, Hideaki Kinugasa, Masahiro Takahara, Keita Harada, Masaki Furukawa, Kouichi Itoshima, Ken Okada, Fumio Otsuka, Scientific Reports.2021;[Epub] CrossRef
Optimal Cutoff Level of Fecal Calprotectin for Detecting Small Bowel Inflammation in Crohn's Disease Eun Soo Kim Gut and Liver.2021; 15(5): 637. CrossRef
Fecal calprotectin predicts complete mucosal healing in patients with ulcerative colitis: Systematic review and meta‑analysis Zhongsheng Cao, Chenglong Ye, Lunan Li, Xiaoge Geng, Wensheng Pan, Jiyong Jing World Academy of Sciences Journal.2021;[Epub] CrossRef
Biochemical Biomarkers of Mucosal Healing for Inflammatory Bowel Disease in Adults Małgorzata Krzystek-Korpacka, Radosław Kempiński, Mariusz Bromke, Katarzyna Neubauer Diagnostics.2020; 10(6): 367. CrossRef
Prostaglandin E-Major Urinary Metabolite Predicts Relapse in Patients With Ulcerative Colitis in Clinical Remission Natsuki Ishida, Kiichi Sugiura, Takahiro Miyazu, Satoshi Tamura, Satoshi Suzuki, Shinya Tani, Mihoko Yamade, Moriya Iwaizumi, Yasushi Hamaya, Satoshi Osawa, Takahisa Furuta, Ken Sugimoto Clinical and Translational Gastroenterology.2020; 11(12): e00289. CrossRef
Prediction of treatment outcome and relapse in inflammatory bowel disease Jun Kato, Takeichi Yoshida, Sakiko Hiraoka Expert Review of Clinical Immunology.2019; 15(6): 667. CrossRef
Background/Aims The exact relationship between vitamin D deficiency and inflammatory bowel disease (IBD) remains unclear. We evaluated the effect of vitamin D3 administration on inflammatory responses and disease severity in patients with IBD.
Methods We investigated the serum 25-hydroxyvitamin D3 [25-(OH)D] and C-reactive protein (CRP) levels and the partial Mayo score (PMS) in patients with IBD. Vitamin D3 was administered in patients with either vitamin D deficiency or insufficiency and CRP serum vitamin D levels and PMS were re-examined at 6 months of administration.
Results In 88 patients with Crohn’s disease (CD), a negative correlation was found between serum vitamin D and CRP. In 178 patients with ulcerative colitis (UC), serum vitamin D showed no association with CRP or PMS. Serum vitamin D increased from 11.08±3.63 to 22.69±6.11 ng/mL in 29 patients with CD and from 11.45±4.10 to 24.20±6.61 ng/mL in 41 patients with UC who received vitamin D3 treatment (P<0.001 and P<0.001, respectively). In patients with CD, median ΔCRP was –0.24 in the normalized vitamin D group and –0.11 in the non-normalized group (P=0.308). In patients with UC, median ΔCRP was −0.01 in the normalized vitamin D group and 0.06 in the non-normalized group (P=0.359).
Conclusions Although a negative correlation was found between serum vitamin D and CRP levels in patients with CD, administration of vitamin D did not improve the CRP level in patients with CD. In patients with UC, serum vitamin D level was unrelated to CRP or PMS.
Citations
Citations to this article as recorded by
The use of vitamin D for patients with inflammatory bowel diseases Júlia Novaes Matias, Vinícius Marinho Lima, Giovanna Soares Nutels, Lucas Fornari Laurindo, Sandra Maria Barbalho, Ricardo de Alvares Goulart, Adriano Cressoni Araújo, Rodrigo Buzinaro Suzuki, Elen Landgraf Guiguer International Journal for Vitamin and Nutrition Research.2024; 94(1): 54. CrossRef
The effect of vitamin D serum levels on the values of C-reactive protein and fecal calprotectin in patients with ulcerative colitis in clinical remission Zarko Krnetic, Tijana Icin, Zeljka Savic, Olgica Latinovic Bosnjak, Vladimir Vracaric, Dimitrije Damjanov, Tatiana Jocic, Radoslav Pejin, Nebojsa Janjic Vojnosanitetski pregled.2024; 81(10): 619. CrossRef
Low Vitamin K and Vitamin D Dietary Intake in Patients with Inflammatory Bowel Diseases Filippo Vernia, Giorgia Burrelli Scotti, Noemi Sara Bertetti, Giuseppe Donato, Stefano Necozione, Piero Vernia, Nadia Pallotta Nutrients.2023; 15(7): 1678. CrossRef
High Risk of Fractures Within 7 Years of Diagnosis in Asian Patients With Inflammatory Bowel Diseases Hyung Jin Ahn, Ye-Jee Kim, Ho-Su Lee, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Beom-Jun Kim, Sang Hyoung Park Clinical Gastroenterology and Hepatology.2022; 20(5): e1022. CrossRef
High Dose Intramuscular Vitamin D3 Supplementation Impacts the Gut Microbiota of Patients With Clostridioides Difficile Infection Sang Hoon Lee, Han-Ki Park, Chang Don Kang, Dae Hee Choi, Sung Chul Park, Jin Myung Park, Seung-Joo Nam, Gi Bong Chae, Kyoung yul Lee, Hyunseok Cho, Sung Joon Lee Frontiers in Cellular and Infection Microbiology.2022;[Epub] CrossRef
Influence of Severe Vitamin D Deficiency on the Clinical Course of Inflammatory Bowel Disease Nam Seok Ham, Sung Wook Hwang, Eun Hye Oh, Jeongseok Kim, Ho-Su Lee, Sang Hyoung Park, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang Digestive Diseases and Sciences.2021; 66(2): 587. CrossRef
Effects of a Single Oral Megadose of Vitamin D3 on Inflammation and Oxidative Stress Markers in Overweight and Obese Women: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Laine de Carvalho Guerra Pessoa Mamede, Rafaela Lira Formiga Cavalcanti de Lima, Alexandre Sérgio Silva, João Carlos Lima Rodrigues Pita, Nadjeanny Ingrid Galdino Gomes, Elisama Araújo de Sena, Rhayra Priscila Moraes Nobrega, João Otávio Scarano Alcântara Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2021; Volume 14: 525. CrossRef
The 25(OH)D3, but Not 1,25(OH)2D3 Levels Are Elevated in IBD Patients Regardless of Vitamin D Supplementation and Do Not Associate with Pain Severity or Frequency Anna Zielińska, Aleksandra Sobolewska-Włodarczyk, Maria Wiśniewska-Jarosińska, Anita Gąsiorowska, Jakub Fichna, Maciej Sałaga Pharmaceuticals.2021; 14(3): 284. CrossRef
The effects of consuming a low-fat yogurt fortified with nano encapsulated vitamin D on serum pro-oxidant-antioxidant balance (PAB) in adults with metabolic syndrome; a randomized control trial Niloofar Taghizadeh, Payam Sharifan, Mansoureh Sadat Ekhteraee Toosi, Fatemeh Najar Sedgh Doust, Susan Darroudi, Asma Afshari, Mitra Rezaie, Mohamad Safarian, Hassan Vatanparast, Saeed Eslami, Hamideh Ghazizadeh, Zahra Khorasanchi, Mohammad Bagherniya, Go Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2021; 15(6): 102332. CrossRef
Vitamin D and inflammatory bowel disease: what do we know so far? Antonio María Caballero Mateos, Raúl Vicente Olmedo-Martín, Amparo Roa-Colomo, María del Mar Díaz Alcázar, Manuel Valenzuela Barranco Revista Española de Enfermedades Digestivas.2020;[Epub] CrossRef
Inflammatory Bowel Disease and Vitamin D Ki Bae Kim, Hyoung Woo Kim, Jun Su Lee, Soon Man Yoon The Korean Journal of Gastroenterology.2020; 76(6): 275. CrossRef
Vitamin D in Inflammatory Bowel Disease: Biological, Clinical and Therapeutic Aspects Raúl Vicente Olmedo-Martín, Inmaculada González-Molero, Gabriel Olveira, Víctor Amo-Trillo, Miguel Jiménez-Pérez Current Drug Metabolism.2019; 20(5): 390. CrossRef
Intraluminal Farnesol and Farnesal in the Mealworm's Alimentary Canal: An Unusual Storage Site Uncovering Hidden Eukaryote Ca2+-Homeostasis-Dependent “Golgicrine” Activities Arnold De Loof, Liliane Schoofs Frontiers in Endocrinology.2019;[Epub] CrossRef
Background/Aims The pharmacokinetics of tacrolimus (TAC) is known to be largely influenced by single-nucleotide polymorphisms (SNPs) in CYP3A5. Patients starting TAC require careful dose adjustment, owing to the wide range of optimal dosages, depending on their CYP3A5 expression status. Here, we evaluated whether individualization of TAC dosages based on CYP3A5 SNPs would improve its therapeutic efficacy in ulcerative colitis.
Methods Twenty-one patients were prospectively treated, with their initial dosage adjusted according to their CYP3A5 status (0.1, 0.15, and 0.2 mg/kg/day for CYP3A5*3/*3, CYP3A5*1/*3, and CYP3A5*1/*1, respectively). Their clinical outcomes were compared with those of patients treated with a fixed dose (0.1 mg/kg/day).
Results The first blood trough level of CYP3A5 expressors, CYP3A5*1/*3 or CYP3A5*1/*1, and the overall rate in achieving the target blood trough level within a week in the individualized-dose group were significantly higher than those in the fixed-dose group (5.15±2.33 ng/mL vs. 9.63±0.79 ng/mL, P=0.035 and 12.5% vs. 66.7%, P=0.01). The remission rate at 2 weeks in the expressors was as high as that in the nonexpressors, CYP3A5*3/*3, in the individualized-dose group.
Conclusions Individualized TAC treatment is effective against ulcerative colitis regardless of the CYP3A5 genotype.
Citations
Citations to this article as recorded by
The impact of cytochrome P450 3A genetic polymorphisms on tacrolimus pharmacokinetics in ulcerative colitis patients Maizumi Furuse, Shuhei Hosomi, Yu Nishida, Shigehiro Itani, Yuji Nadatani, Shusei Fukunaga, Koji Otani, Fumio Tanaka, Yasuaki Nagami, Koichi Taira, Noriko Kamata, Toshio Watanabe, Kenji Watanabe, Yasuhiro Fujiwara, Erika Cecchin PLOS ONE.2021; 16(4): e0250597. CrossRef
Advances in research of tacrolimus for treatment of inflammatory bowel disease Jing-Jing Wang, Yi-Hong Fan World Chinese Journal of Digestology.2019; 27(13): 842. CrossRef
Antonio Carlos da Silva Moraes, Glycia de Freitas Moraes, Antonio Luis Eiras de Araújo, Ronir Raggio Luiz, Celeste Elia, Antonio Jose Carneiro, Heitor Siffert Pereira de Souza
Intest Res 2019;17(2):227-236. Published online April 10, 2019
Background/Aims Consistently defining disease activity remains a critical challenge in the follow-up of patients with Crohn’s disease (CD). We investigated the potential applicability of abdominal ultrasonography with color Doppler (USCD) analysis for the detection of morphological alterations and inflammatory activity in CD.
Methods Forty-three patients with CD ileitis/ileocolitis were evaluated using USCD analysis with measurements obtained on the terminal ileum and right colon. Sonographic parameters included wall thickening, stricture, hyperemia, presence of intra-abdominal mass, and fistulas. Patients were evaluated for the clinical activity (Harvey-Bradshaw Index [HBI]), fecal calprotectin (FC) and C-reactive protein (CRP). The USCD performance was assessed using magnetic resonance enterography (MRE) as a criterion standard.
Results Most measurements obtained with USCD matched the data generated with MRE; however, the agreement improved in clinically active patients where sensitivity, positive predictive value, and accuracy were >80%, considering wall thickening and hyperemia. Complications such as intestinal wall thickening, stricture formation, and hyperemia, were detected in the USCD analysis with moderate agreement with MRE. The best agreement with the USCD analysis was obtained in regard to FC, where the sensitivity, positive predictive value, and accuracy were >70%. The overall performance of USCD was superior to that of HBI, FC and CRP levels, particularly when considering thickening, stricture, and hyperemia parameters.
Conclusions USCD represents a practical noninvasive and low-cost tool for evaluating patients with ileal or ileocolonic disease, particularly in clinically active CD. Therefore, USCD might become a useful asset in the follow-up of patients with CD.
Citations
Citations to this article as recorded by
Diagnostic Accuracy of Intestinal Ultrasound in the Detection of Intra-Abdominal Complications in Crohn’s Disease: A Systematic Review and Meta-Analysis Maarten J Pruijt, Floris A E de Voogd, Nahid S M Montazeri, Faridi S van Etten-Jamaludin, Geert R D’Haens, Krisztina B Gecse Journal of Crohn's and Colitis.2024; 18(6): 958. CrossRef
Comparative study between ultrasound and MR enterography in evaluation of Crohn’s disease Nada Sayed Mahdy, Sahar Mohammed El-Gaafary, Khaled Hamdy Abdel Mageed, Khaled A. Ali Shehata, Maha Ahmed Sayed AbdelKarim, Essam Mohamed Abdulhafiz Egyptian Journal of Radiology and Nuclear Medicine.2024;[Epub] CrossRef
Could ultrasound alone substitute MR imaging in evaluation of Crohn’s disease complications? Hany El-Assaly, Asmaa Abdel Baky Mohamed, Hesham Adel Abdel Fattah Mustafa Egyptian Journal of Radiology and Nuclear Medicine.2024;[Epub] CrossRef
Radiology plus ileocolonoscopy versus radiology alone in Crohn’s disease: prognosis prediction and mutual agreement Hye Kyung Hyun, Jongwook Yu, Eun Ae Kang, Jihye Park, Soo Jung Park, Jae Jun Park, Tae Il Kim, Won Ho Kim, Jae Hee Cheon The Korean Journal of Internal Medicine.2022; 37(3): 567. CrossRef
Comparison of Diagnostic Performance of Ultrasonography and Magnetic Resonance Enterography in the Assessment of Active Bowel Lesions in Patients with Crohn’s Disease: A Systematic Review and Meta-Analysis Da In Lee, Myung-Won You, So Hyun Park, Mirinae Seo, Seong Jin Park Diagnostics.2022; 12(8): 2008. CrossRef
Fistulizing Crohn's disease Amy L. Lightner, Jean H. Ashburn, Mantaj S. Brar, Michele Carvello, Pramodh Chandrasinghe, Anthony de Buck van Overstraeten, Phillip R. Fleshner, Gaetano Gallo, Paulo Gustavo Kotze, Stefan D. Holubar, Lillian M. Reza, Antonino Spinelli, Scott A. Strong, P Current Problems in Surgery.2020; 57(11): 100808. CrossRef
Background/Aims The onset of inflammatory bowel disease (IBD) usually occurs at young age, and therefore, women IBD patients experience pregnancy during their disease progression. Recently, the use of anti-tumor necrosis factor-α (anti-TNF-α) has been rapidly increasing. The aim of this study was to evaluate pregnancy related outcomes in women with IBD who were treated with anti-TNF-α during pregnancy and immunity of their children.
Methods Korean women with IBD who had been treated with anti-TNF-α during pregnancy had been enrolled. Medical records were reviewed and a survey was performed for each patient. For the patients who agreed on additional examination for their children, children’s growth, medical history and antibody to hepatitis B surface antigen (anti-HBs) titer were checked.
Results All 18 patients had been diagnosed with Crohn’s disease. There was not any case of preterm delivery, low birth-weight infant, congenital anomaly, nor stillbirth. All 12 children had followed the regular vaccination schedule for hepatitis B and 4 of them showed negative results for anti-HBs. After the 1 booster vaccination, all children demonstrated seroconversion. Regarding live vaccines, 4 children had bacillus Calmette-Guerin and 4 had rotavirus vaccine before 6 months, without any specific side effects.
Conclusions This was the first study of immunity of the children born from IBD women who had been treated with anti-TNF-α medication during their pregnancy. IBD women had comparable pregnancy outcomes with the general women population, suggesting that the disease activity rather than the administered medication would be more important in healthy pregnancy. Considering the history of vaccination and anti-HBs titers, immunity seems to be intact in the children.
Citations
Citations to this article as recorded by
Safety of Rotavirus Vaccination in Infants That Were Exposed to Biologics In Utero: A Systematic Review Trevor L Schell, Lucas Fass, Mary E Hitchcock, Francis A Farraye, Mary S Hayney, Sumona Saha, Freddy Caldera Inflammatory Bowel Diseases.2024;[Epub] CrossRef
2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases Anne R. Bass, Eliza Chakravarty, Elie A. Akl, Clifton O. Bingham, Leonard Calabrese, Laura C. Cappelli, Sindhu R. Johnson, Lisa F. Imundo, Kevin L. Winthrop, Reuben J. Arasaratnam, Lindsey R. Baden, Roberta Berard, S. Louis Bridges, Jonathan T. L. Cheah, Arthritis & Rheumatology.2023; 75(3): 333. CrossRef
2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases Anne R. Bass, Eliza Chakravarty, Elie A. Akl, Clifton O. Bingham, Leonard Calabrese, Laura C. Cappelli, Sindhu R. Johnson, Lisa F. Imundo, Kevin L. Winthrop, Reuben J. Arasaratnam, Lindsey R. Baden, Roberta Berard, S. Louis Bridges, Jonathan T. L. Cheah, Arthritis Care & Research.2023; 75(3): 449. CrossRef
Society for Maternal-Fetal Medicine Consult Series #64: Systemic lupus erythematosus in pregnancy Robert Silver, Sabrina Craigo, Flint Porter, Sarah S. Osmundson, Jeffrey A. Kuller, Mary E. Norton American Journal of Obstetrics and Gynecology.2023; 228(3): B41. CrossRef
Vaccines in Children Exposed to Biological AgentsIn Uteroand/or During Breastfeeding: Are They Effective and Safe? Javier P Gisbert, María Chaparro Journal of Crohn's and Colitis.2023; 17(6): 995. CrossRef
Vaccination for rheumatic diseases: Current issues (based on ACR guidelines) B. S. Belov, N. V. Muravyeva, E. L. Nasonov Rheumatology Science and Practice.2023; 61(2): 151. CrossRef
Pregnancy Outcomes Associated With Biologic Agent Exposure in Patients With Several Rheumatic Diseases and Inflammatory Bowel Diseases Soo Min Ahn, Young Bin Joo, Yun Jin Kim, So-Young Bang, Hye-Soon Lee Journal of Korean Medical Science.2023;[Epub] CrossRef
Modern Ideas about Vaccination of Patients with Rheumatic Diseases: the View of ACR Experts B. S. Belov, N. V. Muravyeva Antibiotics and Chemotherapy.2023; 68(5-6): 77. CrossRef
Suboptimal Vaccination Administration in Mothers With Inflammatory Bowel Disease and Their Biologic-Exposed Infants Helene Chiarella-Redfern, Sangmin Lee, Bellal Jubran, Nastaran Sharifi, Remo Panaccione, Cora Constantinescu, Eric I Benchimol, Cynthia H Seow Inflammatory Bowel Diseases.2022; 28(1): 79. CrossRef
A systematic review of live vaccine outcomes in infants exposed to biologic disease modifying anti-rheumatic drugs in utero
Bethan Goulden, Nicole Chua, Elaine Parker, Ian Giles Rheumatology.2022; 61(10): 3902. CrossRef
The Risk of Adverse Neonatal Outcomes With Maternal Inflammatory Bowel Disease: A Systematic Review and Meta-analysis Kristel K Leung, Parul Tandon, Vivek Govardhanam, Cynthia Maxwell, Vivian Huang Inflammatory Bowel Diseases.2021; 27(4): 550. CrossRef
The Influence of Disease Activity on Pregnancy Outcomes in Women With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis Min-A Kim, Young-Han Kim, Jaeyoung Chun, Hye Sun Lee, Soo Jung Park, Jae Hee Cheon, Tae Il Kim, Won Ho Kim, Jae Jun Park Journal of Crohn's and Colitis.2021; 15(5): 719. CrossRef
Biologics During Pregnancy and Breastfeeding Among Women With Rheumatic Diseases: Safety Clinical Evidence on the Road Asmaa Beltagy, Azin Aghamajidi, Laura Trespidi, Wally Ossola, Pier Luigi Meroni Frontiers in Pharmacology.2021;[Epub] CrossRef
ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease T Kucharzik, P Ellul, T Greuter, J F Rahier, B Verstockt, C Abreu, A Albuquerque, M Allocca, M Esteve, F A Farraye, H Gordon, K Karmiris, U Kopylov, J Kirchgesner, E MacMahon, F Magro, C Maaser, L de Ridder, C Taxonera, M Toruner, L Tremblay, M Scharl, N Journal of Crohn's and Colitis.2021; 15(6): 879. CrossRef
Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)—Part 1: Live Vaccines Eric I. Benchimol, Frances Tse, Matthew W. Carroll, Jennifer C. deBruyn, Shelly A. McNeil, Anne Pham-Huy, Cynthia H. Seow, Lisa L. Barrett, Talat Bessissow, Nicholas Carman, Gil Y. Melmed, Otto G. Vanderkooi, John K. Marshall, Jennifer L. Jones Gastroenterology.2021; 161(2): 669. CrossRef
Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)—Part 1: Live Vaccines Eric I Benchimol, Frances Tse, Matthew W Carroll, Jennifer C deBruyn, Shelly A McNeil, Anne Pham-Huy, Cynthia H Seow, Lisa L Barrett, Talat Bessissow, Nicholas Carman, Gil Y Melmed, Otto G Vanderkooi, John K Marshall, Jennifer L Jones Journal of the Canadian Association of Gastroenterology.2021; 4(4): e59. CrossRef
Systematic review with meta‐analysis: risk of adverse pregnancy‐related outcomes in inflammatory bowel disease Parul Tandon, Vivek Govardhanam, Kristel Leung, Cynthia Maxwell, Vivian Huang Alimentary Pharmacology & Therapeutics.2020; 51(3): 320. CrossRef
Safety and Optimal Timing of BCG Vaccination in Infants Born to Mothers Receiving Anti-TNF Therapy for Inflammatory Bowel Disease Sang Hyoung Park, Hyo Jong Kim, Chang Kyun Lee, Eun Mi Song, Sang-Bum Kang, Byung Ik Jang, Eun Soo Kim, Kyeong Ok Kim, Yoo Jin Lee, Eun Young Kim, Yun Jin Jung, Soo-Kyung Park, Dong Il Park, Byong Duk Ye, Sung-Ae Jung, Suk-Kyun Yang Journal of Crohn's and Colitis.2020; 14(12): 1780. CrossRef
Intrauterine Exposure to Biologics in Inflammatory Autoimmune Diseases: A Systematic Review N. Ghalandari, R. J. E. M. Dolhain, J. M. W. Hazes, E. P. van Puijenbroek, M. Kapur, H. J. M. J. Crijns Drugs.2020; 80(16): 1699. CrossRef
Background/Aims Optimal management of inflammatory bowel disease (IBD) with concomitant Clostridium difficile infection (CDI) is controversial, especially when CDI diagnosis is made by polymerase chain reaction (PCR) testing, which may reflect colonization without infection.
Methods We performed a multicenter review of all inpatients with IBD and PCR diagnosed CDI. Outcomes included length of stay, 30- and 90-day readmission, colectomy during admission and within 3 months, intensive care unit (ICU) admission, CDI relapse and death for patients who received corticosteroid (CS) after CDI diagnosis versus those that did not. Propensity-adjusted regression analysis of outcomes based on CS usage was performed.
Results We identified 177 IBD patients with CDI, 112 ulcerative colitis and 65 Crohn’s disease. For IBD overall, CS after CDI diagnosis was associated with prolonged hospitalization (5.5 days: 95% confidence interval [CI], 1.5–9.6 days; P=0.008), higher colectomy rate within 3 months (odds ratio [OR], 5.5; 95% CI, 1.1–28.2; P=0.042) and more frequent ICU admissions (OR, 7.8; 95% CI, 1.5–41.6; P=0.017) versus no CS. CS use post-CDI diagnosis in UC patients was associated with prolonged hospitalization (6.2 days: 95% CI, 0.4– 12.0 days; P=0.036) and more frequent ICU admissions (OR, 7.4; 95% CI, 1.1–48.7; P=0.036).
Conclusions CS use among IBD inpatients with CDI diagnosed by PCR is associated with poorer outcomes and would seem to reinforce the importance of C. difficile toxin assay to help distinguish colonization from infection. This adverse effect appears more prominent among those with UC.
Citations
Citations to this article as recorded by
Clostridioides difficile infection in inflammatory bowel disease: a clinical review Mengjun Tang, Chunhua Wang, Ying Xia, Jian Tang, Jiao Wang, Liang Shen Expert Review of Anti-infective Therapy.2024; 22(5): 297. CrossRef
The Current Knowledge on Clostridioides difficile Infection in Patients with Inflammatory Bowel Diseases Alina Boeriu, Adina Roman, Crina Fofiu, Daniela Dobru Pathogens.2022; 11(7): 819. CrossRef
Korean Association for the Study of Intestinal Diseases guidance for clinical practice of adult inflammatory bowel disease during the coronavirus disease 2019 pandemic: expert consensus statements Yong Eun Park, Yoo Jin Lee, Ji Young Chang, Hyun Joo Song, Duk Hwan Kim, Young Joo Yang, Byung Chang Kim, Jae Gon Lee, Hee Chan Yang, Miyoung Choi, Seong-Eun Kim, Seung-Jae Myung Intestinal Research.2022; 20(4): 431. CrossRef
KASID Guidance for Clinical Practice Management of Adult Inflammatory Bowel Disease during the COVID-19 Pandemic: Expert Consensus Statement Yong Eun Park, Yoo Jin Lee, Ji Young Chang, Hyun Joo Song, Duk Hwan Kim, Young Joo Yang, Byung Chang Kim, Jae Gon Lee, Hee Chan Yang, Miyoung Choi, Seong-Eun Kim, Seung-Jae Myung The Korean Journal of Gastroenterology.2021; 78(2): 105. CrossRef
Ji Yeon Kim, Sungkyoung Choi, Taesung Park, Seul Ki Kim, Yoon Suk Jung, Jung Ho Park, Hong Joo Kim, Yong Kyun Cho, Chong Il Sohn, Woo Kyu Jeon, Byung Ik Kim, Kyu Yong Choi, Dong Il Park
Intest Res 2019;17(2):253-264. Published online November 20, 2018
Background/Aims Colorectal cancer incidence among patients aged ≤50 years is increasing. This study aimed to develop and validate an advanced colorectal neoplasm (ACRN) screening model for young adults aged <50 years in Korea.
Methods This retrospective cross-sectional study included 59,575 consecutive asymptomatic Koreans who underwent screening colonoscopy between 2003 and 2012 at a single comprehensive health care center. Young Adult Colorectal Screening (YCS) score was developed as an optimized risk stratification model for ACRN using multivariate analysis and was internally validated. The predictive power and diagnostic performance of YCS score was compared with those of Asia-Pacific Colorectal Screening (APCS) and Korean Colorectal Screening (KCS) scores.
Results 41,702 and 17,873 subjects were randomly allocated into the derivation and validation cohorts, respectively, by examination year. ACRN prevalence was 0.9% in both cohorts. YCS score comprised sex, age, alcohol, smoking, obesity, glucose metabolism abnormality, and family history of CRC, with score ranges of 0 to 10. In the validation cohort, ACRN prevalence was 0.6% in the low-risk tier (score, 0–4), 1.5% in the moderate-risk tier (score, 5–7), and 3.4% in the high-risk tier (score, 8–10). ACRN risk increased 2.5-fold (95%CI, 1.8–3.4) in the moderate-risk tier and 5.8-fold (95%CI, 3.4–9.8) in the high-risk tier compared with the low-risk tier. YCS score identified better balanced accuracy (53.9%) than APCS (51.5%) and KCS (50.7%) scores and had relatively good discriminative power (area under the curve=0.660).
Conclusions YCS score based on clinical and laboratory risk factors was clinically effective and beneficial for predicting ACRN risk and targeting screening colonoscopy in adults aged <50 years.
Citations
Citations to this article as recorded by
Performance of the Asia–Pacific Colorectal Screening score in stratifying the risk of advanced colorectal neoplasia: A meta‐analysis and systematic review Mai Ngoc Luu, Nhi Ai Trinh, Truc Le Thanh Tran, Thinh Phuong Dang, Toru Hiyama, Duc Trong Quach Journal of Gastroenterology and Hepatology.2024; 39(6): 1000. CrossRef
Response to commentaries on “Performance of the Asia‐Pacific colorectal screening score in stratifying the risk of advanced colorectal neoplasia: A meta‐analysis and systematic review” MN Luu, DT Quach Journal of Gastroenterology and Hepatology.2024;[Epub] CrossRef
Updated epidemiology of gastrointestinal cancers in East Asia Junjie Huang, Don Eliseo Lucero-Prisno, Lin Zhang, Wanghong Xu, Sunny H. Wong, Siew C. Ng, Martin C. S. Wong Nature Reviews Gastroenterology & Hepatology.2023; 20(5): 271. CrossRef
From Algorithms to Clinical Utility: A Systematic Review of Individualized Risk Prediction Models for Colorectal Cancer Deborah Jael Herrera, Wessel van de Veerdonk, Daiane Maria Seibert, Moges Muluneh Boke, Claudia Gutiérrez-Ortiz, Nigus Bililign Yimer, Karen Feyen, Allegra Ferrari, Guido Van Hal Gastrointestinal Disorders.2023; 5(4): 549. CrossRef
Emergence of a New Optical Marker for Colorectal Neoplasms: To What Extent Should We Accept It? Han Hee Lee Clinical Endoscopy.2022; 55(2): 315. CrossRef
Is early-onset cancer an emerging global epidemic? Current evidence and future implications Tomotaka Ugai, Naoko Sasamoto, Hwa-Young Lee, Mariko Ando, Mingyang Song, Rulla M. Tamimi, Ichiro Kawachi, Peter T. Campbell, Edward L. Giovannucci, Elisabete Weiderpass, Timothy R. Rebbeck, Shuji Ogino Nature Reviews Clinical Oncology.2022; 19(10): 656. CrossRef
Strategies for colorectal cancer screening and post-polypectomy surveillance for young adults under age 50 Yoon Suk Jung Precision and Future Medicine.2021; 5(2): 69. CrossRef
How to Choose the Optimal Bowel Preparation Regimen for Colonoscopy Ji Eun Na, Eun Ran Kim The Ewha Medical Journal.2021; 44(4): 122. CrossRef
The Role of Diet and Lifestyle in Early-Onset Colorectal Cancer: A Systematic Review Marta Puzzono, Alessandro Mannucci, Simone Grannò, Raffaella Alessia Zuppardo, Andrea Galli, Silvio Danese, Giulia Martina Cavestro Cancers.2021; 13(23): 5933. CrossRef
Association between waist circumference and risk of colorectal neoplasia in normal‐weight adults Yoon Suk Jung, Nam Hee Kim, Hyo‐Joon Yang, Soo‐Kyung Park, Jung Ho Park, Dong Il Park, Chong Il Sohn Journal of Gastroenterology and Hepatology.2020; 35(1): 43. CrossRef
Risk prediction rule for advanced neoplasia on screening colonoscopy for average-risk individuals Ala I Sharara, Ali El Mokahal, Ali H Harb, Natalia Khalaf, Fayez S Sarkis, Mustapha M El-Halabi, Nabil M Mansour, Ahmad Malli, Robert Habib World Journal of Gastroenterology.2020; 26(37): 5705. CrossRef
Risk Factors Associated With Young-Onset Colorectal Adenomas and Cancer: A Systematic Review and Meta-Analysis of Observational Research Genevieve Breau, Ursula Ellis Cancer Control.2020;[Epub] CrossRef
Prevalence and risk factors of colorectal cancer in Asia Martin CS Wong, Hanyue Ding, Jingxuan Wang, Paul SF Chan, Junjie Huang Intestinal Research.2019; 17(3): 317. CrossRef
Background/Aims There are few prospective studies on cold forceps polypectomy (CFP) using jumbo cup forceps. Therefore, we examined patients with diminutive polyps (5 mm or smaller) treated with CFP using jumbo cup forceps to achieve an adenoma-free colon and also assessed the safety of the procedure and the recurrence rate of missed or residual polyp after CFP by performing follow-up colonoscopy 1 year later.
Methods We included patients with up to 5 adenomas removed at initial colonoscopy and analyzed data from a total of 361 patients with 573 adenomas. One-year follow-up colonoscopy was performed in 165 patients, at which 251 lesions were confirmed.
Results The one-bite resection rate with CFP was highest for lesions 3 mm or smaller and decreased significantly with increasing lesion size. Post-procedural hemorrhage was observed in 1 of 573 lesions (0.17%). No perforation was noted. The definite recurrence rate was 0.8% (2/251 lesions). The probable recurrence rate, which was defined as recurrence in the same colorectal segment, was 17%. Adenoma-free colon was achieved in 55% of patients at initial resection. Multivariate analysis revealed that achievement of an adenoma-free colon was significantly associated with number of adenomas and years of endoscopic experience.
Conclusions CFP using jumbo biopsy forceps was safe and showed a high one-bite resection rate for diminutive lesions of 3 mm or smaller. The low definite recurrence rate confirms the reliability of CFP using jumbo biopsy forceps. Number of adenomas and years of endoscopic experience were key factors in achieving an adenoma-free colon.
Citations
Citations to this article as recorded by
Polypectomy for Diminutive and Small Colorectal Polyps Melissa Zarandi-Nowroozi, Roupen Djinbachian, Daniel von Renteln Gastrointestinal Endoscopy Clinics of North America.2022; 32(2): 241. CrossRef
Cold Snare Resection of Colorectal Polyps: Updates and Recent Developments Roupen Djinbachian, Daniel von Renteln Current Treatment Options in Gastroenterology.2022; 20(3): 221. CrossRef
Prospective multicenter study of the efficacy and safety of cold forceps polypectomy for ≤ 6-mm non-ampullary duodenal low-grade adenomas Hiromitsu Kanzaki, Joichiro Horii, Ryuta Takenaka, Hiroyuki Nakagawa, Kazuhiro Matsueda, Takao Tsuzuki, Masahide Kita, Yasushi Yamasaki, Takehiro Tanaka, Masaya Iwamuro, Seiji Kawano, Yoshiro Kawahara, Jun Tomoda, Hiroyuki Okada Endoscopy International Open.2022; 10(06): E712. CrossRef
Endoscopic resection of local recurrences of diminutive polyps by cold forceps polypectomy Toshio Kuwai, Takuya Yamada, Tatsuya Toyokawa, Tomohiro Kudo, Naoki Esaka, Hajime Ohta, Haruhiro Yamashita, Yasuo Hosoda, Noriko Watanabe, Naohiko Harada Scandinavian Journal of Gastroenterology.2021; 56(3): 363. CrossRef
How to Approach Small Polyps in Colon: Tips and Tricks Sultan Mahmood, Enrik John Aguila, Asad ur Rahman, Asim Shuja, Steven Bollipo Techniques and Innovations in Gastrointestinal Endoscopy.2021; 23(4): 328. CrossRef
Risk factors for incomplete polyp resection during colonoscopy Weifeng Lao, Pankaj Prasoon, Gaoyang Cao, Lian Tat Tan, Sheng Dai, Giridhar Hanumappa Devadasar, Xuefeng Huang Laparoscopic, Endoscopic and Robotic Surgery.2021;[Epub] CrossRef
Rates of Incomplete Resection of 1- to 20-mm Colorectal Polyps: A Systematic Review and Meta-Analysis Roupen Djinbachian, Ryma Iratni, Madeleine Durand, Paola Marques, Daniel von Renteln Gastroenterology.2020; 159(3): 904. CrossRef
Child-Pugh B or C Cirrhosis Increases the Risk for Bleeding Following Colonoscopic Polypectomy Hosim Soh, Jaeyoung Chun, Seung Wook Hong, Seona Park, Yun Bin Lee, Hyun Jung Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jong Pil Im, Yoon Jun Kim, Joo Sung Kim, Jung-Hwan Yoon Gut and Liver.2020; 14(6): 755. CrossRef
Although ulcerative colitis (UC) is confined to colonic and rectal mucosa in a continuous fashion, recent studies have also demonstrated the involvement of upper gastrointestinal tract as diagnostic endoscopy becomes more available and technically advanced. The pathogenesis of UC is not well established yet. It might be associated with an inappropriate response of host mucosal immune system to gut microflora. Although continuous and symmetric distribution of mucosal inflammation from rectum to colon is a typical pattern of UC, clinical feature and course of atypically distributed lesions in UC might also help us understand the pathogenesis of UC. Herein, we report a case of duodenal involvement of UC which successfully remitted after infliximab therapy. Endoscopic and pathologic findings before and after administration of anti-tumor necrosis factor suggest that the pathogenesis of upper gastrointestinal involvement of UC may be similar to that of colon involvement.
Citations
Citations to this article as recorded by
Gastroduodenitis Associated with Active Ulcerative Colitis Treated with Infliximab: Different Clinical Course in the Colon and Gastroduodenal Lesions Tomoyuki Hayashi, Takeshi Terashima, Masaki Nishitani, Noriaki Orita, Masaki Miyazawa, Akihiro Seki, Hidetoshi Nakagawa, Kouki Nio, Noriho Iida, Shinya Yamada, Hajime Takatori, Tetsuro Shimakami, Taro Yamashita Internal Medicine.2024; 63(7): 929. CrossRef
Severe Disease Activity May Predispose Patients to Post-colectomy Duodenitis Associated with Ulcerative Colitis Akira Sonoda, Naoki Yoshimura, Minako Sako, Soh Okano, Satoshi Saito, Masakazu Takazoe, Satomi Furukawa, Kinya Okamoto, Tetsuo Yamana, Hisateru Tachimori, Masayuki Fukata Internal Medicine.2024; 63(10): 1337. CrossRef
Concurrent occurrence of ulcerative duodenitis and ulcerative colitis displaying unique responses to golimumab and ustekinumab Sho Masaki, Hajime Honjo, Masayuki Kurimoto, Natsuki Okai, Yasuo Otsuka, Yasuhiro Masuta, Ken Kamata, Kosuke Minaga, Masatoshi Kudo, Tomohiro Watanabe Clinical Journal of Gastroenterology.2024; 17(5): 854. CrossRef
Upper Gastrointestinal Tract Involvement in Inflammatory Bowel Diseases: Histologic Clues and Pitfalls Bence Kővári, Rish K. Pai Advances in Anatomic Pathology.2022; 29(1): 2. CrossRef
Mucosal lesions of the upper gastrointestinal tract in patients with ulcerative colitis: A review Yan Sun, Zhe Zhang, Chang-Qing Zheng, Li-Xuan Sang World Journal of Gastroenterology.2021; 27(22): 2963. CrossRef
Clinical characteristics and prognosis of patients with ulcerative colitis that shows rectal sparing at initial diagnosis Yong-Sung Choi, Jong-Kyu Kim, Wan-Jung Kim World Journal of Gastrointestinal Endoscopy.2021; 13(9): 407. CrossRef
Upper Gastrointestinal Manifestations of Inflammatory Bowel Disease Noam Harpaz, Alexandros D. Polydorides Surgical Pathology Clinics.2020; 13(3): 413. CrossRef
Two Cases of Ulcerative Colitis-like Gastroduodenitis after Total Proctocolectomy for Intractable Ulcerative Colitis Takahiro SHIMOYAMA, Takayuki YAMAMOTO, Yasuhiro INOUE, Satoru UMEGAE Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association).2019; 80(5): 904. CrossRef
Underutilization of Aspirin in Patients With Advanced Colorectal Polyps Benjamin Fiedler, Lawrence Fiedler, Michael DeDonno, Kosi Anago, Leonie de la Cruz, George R. Luck, Charles H. Hennekens The American Journal of Medicine.2019;[Epub] CrossRef